Menu Back toSession-7-Epidemiology-and-RWE

Pharmacovigilance and Risk Management Strategies Conference

NEW! The 2019 meeting will be a full three days, allowing maximum learning opportunities!


Session 7: Generating Real World Evidence (RWE) Fit for Regulatory Decisions: Learning from Safety

Session Chair(s)

Annette  Stemhagen, DrPH, FISPE

Annette Stemhagen, DrPH, FISPE

  • SVP, Chief Scientific Officer
  • UBC, United States
Robert  Reynolds, DrSc, MSc, FISPE

Robert Reynolds, DrSc, MSc, FISPE

  • Vice President, Epidemiology, Worldwide Regulatory and Safety
  • Pfizer Inc, United States
Tools and expertise exist in pharmacovigilance to ensure that real world data meet the necessary quality standards for regulatory decisions. Studies are already being designed in accordance with current best practices to reduce bias and produce valid results. This session builds on the long standing use of RWE in PV to provide lessons, case studies, and guidances relevant to the goal of developing a broader framework for integrating RWE in regulatory decision making.
Learning Objective : Upon completion of this session, the participant should be able to:
  • Describe the common uses of RWE in pharmacovigilance and risk management
  • Summarize the key scientific criteria for evaluating the quality of RWE for regulatory decisions
  • Identify circumstances where RWE may appropriately supplement drug development

Speaker(s)

Sebastian  Schneeweiss, DrSc, MD, MS, FISPE

When and How can RWD Analyses Support Regulator Decision-Making

Sebastian Schneeweiss, DrSc, MD, MS, FISPE

  • Professor of Medicine and Epidemiology
  • Harvard Medical School and Brigham & Women's Hospital, United States
Cathy  Critchlow

RWE for Drug Development and Regulatory Approvals

Cathy Critchlow

  • Vice President, Center for Observational Research
  • Amgen Inc., United States
David  Martin, MD, MPH

21st Century Cures and the evaluation of RWE at FDA

David Martin, MD, MPH

  • Associate Director for Real World Evidence Analytics, OMP, CDER
  • FDA, United States
Cathy  Critchlow

Panelists

Cathy Critchlow

  • Vice President, Center for Observational Research
  • Amgen Inc., United States
Andrew  Robertson, JD, PhD

Panelists

Andrew Robertson, JD, PhD

  • Head, Global Regulatory Science and Policy, NA
  • Sanofi, United States